BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects
Phase 1
Completed
- Conditions
- Renal Insufficiency, Chronic
- Interventions
- Drug: Molidustat(BAY85-3934)
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT02312973
Radium-223 Dichloride Long-term Follow-up Program
Phase 4
Completed
- Conditions
- Neoplasm Metastasis / Bone and Bones
- Interventions
- Other: Data Collection
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 255
- Registration Number
- NCT02312960
EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
Phase 2
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2014-12-05
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 46
- Registration Number
- NCT02309411
- Locations
- πΊπΈ
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration
Phase 4
Completed
- Conditions
- Wet Macular Degeneration
- Interventions
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 288
- Registration Number
- NCT02305238
An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
Completed
- Conditions
- Thyroid Neoplasms
- Interventions
- Drug: Sorafenib (Nexavar, BAY43-9006)Drug: Other Multikinase inhibitors
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 667
- Registration Number
- NCT02303444
Efficacy and Safety of Polyethylene Glycol 3350 (PEG 3350) for Relief of Constipation (MK-8114-005)
Phase 3
Withdrawn
- Conditions
- Constipation
- Interventions
- Drug: Polyethylene Glycol 3350 Powder for Solution (PEG 3350)Drug: Polyethylene Glycol 4000 Powder for Solution (PEG 4000)
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Bayer
- Registration Number
- NCT02292459
Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
Completed
- Conditions
- Wet Macular Degeneration
- Interventions
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 912
- Registration Number
- NCT02289924
A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?
Phase 4
Terminated
- Conditions
- Physician Education
- Interventions
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 23
- Registration Number
- NCT02287025
Colorado Adult Joint Assessment Scale (CAJAS) Validation
Not Applicable
Completed
- Conditions
- Hemophilia A
- Interventions
- Other: Colorado Adult Joint Assessment Evaluation
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT02284789
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
Phase 2
Completed
- Conditions
- Scleroderma, Systemic
- Interventions
- Drug: Riociguat (Adempas, BAY63-2521)Drug: Placebo
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 121
- Registration Number
- NCT02283762
- Locations
- π¨π¦
Mount Sinai Hospital, Toronto, Ontario, Canada
π¦πΊRoyal Perth Hospital, Perth, Western Australia, Australia
π¬π§Hope Hospital, Salford, Manchester, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath